Migraine attacks can be debilitating, with painful headaches lasting for days. Fortunately, there are medications available to help manage symptoms, with triptans being a common option to treat acute migraine attacks. A systematic review and network meta-analysis published in The BMJ compared oral monotherapy options for migraines, looking at data from 137 randomized controlled trials involving almost 90,000 individuals.
The review found that eletriptan was the most effective at eliminating pain after 2 hours, with other top performers including rizatriptan, sumatriptan, and zolmitriptan. The evidence also suggested that certain triptans are more effective than newer migraine medications like lasmiditan and ubrogepant. These findings may help guide treatment recommendations in the future and could lead to a revision of existing guidelines.
Study author Andrea Cipriani noted that specific triptans are underused despite their effectiveness, and this study could help raise awareness of their efficacy. However, it is crucial to consider potential side effects and contraindications when prescribing triptans, as they may not be suitable for individuals with certain health conditions. It is also important to have discussions with healthcare providers to ensure optimal patient care.
Migraine affects around 10% of the global population, making it important to have effective treatment options available. The study results highlight the need for better information for healthcare professionals and policymakers to ensure that patients receive appropriate care. While triptans are already a recommended treatment for migraine, this review emphasizes the need for providers to consider the most effective options for individual patients.
Despite the study’s limitations, such as potential bias in some of the included trials, the findings underscore the effectiveness of certain triptans for treating acute migraine attacks. It is essential to continue research in this area and to include more diverse study cohorts in the future to ensure comprehensive treatment recommendations. Overall, this review provides valuable insights that can help improve the management of migraine symptoms and guide future treatment recommendations.
